Centessa Pharmaceuticals (NASDAQ:CNTA) Sees Strong Trading Volume – Time to Buy?

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) saw an uptick in trading volume on Wednesday . 3,050,666 shares changed hands during trading, an increase of 90% from the previous session’s volume of 1,607,597 shares.The stock last traded at $22.79 and had previously closed at $22.92.

Analyst Ratings Changes

A number of research analysts have issued reports on CNTA shares. Piper Sandler reaffirmed an “overweight” rating on shares of Centessa Pharmaceuticals in a report on Friday, January 16th. Cowen reissued a “buy” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 14th. Wall Street Zen raised Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, October 27th. Oppenheimer increased their price target on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the stock an “outperform” rating in a report on Wednesday, December 10th. Finally, Truist Financial lifted their price objective on shares of Centessa Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $38.00.

Centessa Pharmaceuticals Stock Performance

The business’s 50-day simple moving average is $25.96 and its two-hundred day simple moving average is $21.88. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. The firm has a market cap of $3.12 billion, a price-to-earnings ratio of -12.69 and a beta of 1.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). As a group, sell-side analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

Insider Activity at Centessa Pharmaceuticals

In related news, insider Mario Alberto Accardi sold 10,000 shares of the stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $30.00, for a total value of $300,000.00. Following the completion of the sale, the insider owned 178,801 shares of the company’s stock, valued at approximately $5,364,030. This trade represents a 5.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CTO Tia L. Bush sold 40,000 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $26.00, for a total value of $1,040,000.00. Following the completion of the sale, the chief technology officer directly owned 121,503 shares of the company’s stock, valued at $3,159,078. This trade represents a 24.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 58,000 shares of company stock valued at $1,540,000 over the last quarter. 7.09% of the stock is owned by company insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Centessa Pharmaceuticals in the 2nd quarter valued at $218,000. DNB Asset Management AS purchased a new position in Centessa Pharmaceuticals in the 3rd quarter valued at approximately $218,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Centessa Pharmaceuticals by 4.8% in the second quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company’s stock worth $252,000 after acquiring an additional 870 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Centessa Pharmaceuticals in the third quarter valued at $455,000. Finally, BNP Paribas Financial Markets boosted its holdings in Centessa Pharmaceuticals by 3,028.1% in the second quarter. BNP Paribas Financial Markets now owns 34,972 shares of the company’s stock valued at $460,000 after purchasing an additional 33,854 shares during the period. Hedge funds and other institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.